NR1H4 and primary biliary cholangitis: A Phase 2 clinical trial (NCT02943447) of another nonsteroidal FXR agonist, Cilofexor (GS-9674) yield promising results, with 9% of PBC patients reached the target endpoint of ALP less than 1.67 ULN in the 30-mg group and 14% in 100-mg group.